Cell & Gene: The Podcast Scaling Allo with Allogene Therapeutics' Dr. Zachary Roberts
Aug 29, 2024
Dr. Zachary Roberts, EVP of R&D and CMO at Allogene Therapeutics, dives into the complexities of chronic lymphocytic leukemia (CLL) and critiques existing CAR T therapies. He emphasizes why allogeneic approaches may offer a scalable and effective solution. The conversation highlights the advantages of allogeneic cell therapies, their impact on treatment accessibility, and the promising Phase Two Alpha-3 trial. Furthermore, Dr. Roberts discusses novel advancements in CAR T therapies and their potential applications in treating both cancer and autoimmune diseases.
Chapters
Transcript
Episode notes
1 2 3 4 5
Intro
00:00 • 2min
Advancements in Allogeneic Cell Therapies
02:28 • 13min
Exploring the Phase Two Alpha-3 Trial and the Impact of Disease Burden on Treatment Outcomes
15:05 • 1min
Innovations in CAR T Therapy for Lymphoma Treatment
16:32 • 5min
Exciting Developments in CAR T Therapy and Autoimmune Treatment
21:31 • 3min